Dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis in adults.

Patients with AD are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus vs dupilumab alone.

Registration is open for the inaugural Atopic Dermatitis Summit. The virtual even will be held on Saturday, April 23, 2022 at 10am EDT.

A retrospective review has revealed that eczema can be associated with a 63% increased chance of patients also developing either...

A new study found difamilast ointment 1% to be safe and efficacious in the treatment of atopic dermatitis.

Dupilumab-induced ocular surface disease appears to occur more frequently in patients with AD than with other skin conditions.

A research letter published in the Journal of the American Academy of Dermatology has outlined the degree to which symptoms of atopic...

Adult patients with moderate-to-severe AD being treated with dupilumab had lower rates of hospitalization and shorter stays.